瑞博生物-B于12月31日至1月6日招股，获基石投资认购约1亿美元

Core Viewpoint - The company, Ribocure AB, is set to launch an IPO with a global offering of 27.4874 million H-shares at a price of HKD 57.97 per share, aiming to raise approximately HKD 1.474 billion for its drug development pipeline, particularly focusing on siRNA therapies for various diseases [1][3]. Group 1: IPO Details - The IPO will take place from December 31, 2025, to January 6, 2026, with 10% of the shares allocated for the Hong Kong offering and 90% for international investors, including an overallotment option of 15% [1]. - The shares are expected to commence trading on the Hong Kong Stock Exchange on January 9, 2026 [1]. Group 2: Product Pipeline - Ribocure AB specializes in small nucleic acid drug research and development, particularly focusing on siRNA therapies, with a core product, RBD4059, targeting FXI for thrombotic disease treatment [1]. - The company has seven self-developed drug assets in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1]. - In addition to RBD4059, the company is advancing other clinical-stage products, including RBD5044, the second siRNA drug targeting APOC3 in clinical development globally, and RBD1016, aimed at achieving functional cure for chronic hepatitis B [1]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 1.474 billion from the global offering will be allocated as follows: 37.4% for RBD4059 development, 19.6% for RBD5044, 15.9% for RBD1016, 10.1% for preclinical assets, 8.9% for advancing preclinical projects, and 8.1% for working capital and general corporate purposes [3]. Group 4: Cornerstone Investors - The company has entered into cornerstone investment agreements with several investors, including Arc Avenue and Bright Stone, who have committed to subscribe for shares amounting to approximately USD 100 million, reflecting confidence in the company's business prospects [2].